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Abstract
Dengue virus (DENV) is an emerging mosquito-borne pathogen that causes cytokine-mediated alterations in the barrier
function of the microvascular endothelium, leading to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
We observed that DENV (serotype 2) productively infects primary (HMVEC-d) and immortalized (HMEC-1) human dermal
microvascular endothelial cells, despite the absence of well-described DENV receptors, such as dendritic cell-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) or the mannose receptor on the cell surface. However,
heparan sulfate proteoglycans (HSPGs) were highly expressed on these cells and pre-treatment of HMEC-1 cells with
heparinase II or with glycosaminoglycans reduced DENV infectivity up to 90%, suggesting that DENV uses HSPGs as
attachment receptor on microvascular endothelial cells. Sulfated Escherichia coli K5 derivatives, which are structurally similar
to heparin/heparan sulfate but lack anticoagulant activity, were able to block DENV infection of HMEC-1 and HMVEC-d cells
in the nanomolar range. The highly sulfated K5-OS(H) and K5-N,OS(H) inhibited virus attachment and subsequent entry into
microvascular endothelial cells by interacting with the viral envelope (E) protein, as shown by surface plasmon resonance
(SPR) analysis using the receptor-binding domain III of the E protein.
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Introduction
Dengue virus (DENV) is a mosquito-borne flavivirus that infects
50–100 million people each year, resulting in 500,000 hospital-
izations and 25,000 deaths [1,2]. Four closely related serotypes are
known (DENV 1–4), which cause similar clinical manifestations,
ranging from an acute self-limiting flu-like illness called dengue
fever (DF) to the more severe and potentially life-threatening
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). The latter are characterized by thrombocytopenia,
increased capillary permeability and plasma leakage. Infection
with one serotype leads to lifelong immunity against the same
serotype, but only to partial and temporal immunity against the
other serotypes [2]. Although a lot of research has been done on
DENV, the pathogenesis of DHF/DSS is still not completely
understood and no vaccine or antiviral treatment is available [2–
5].
Dendritic cells, monocytes and macrophages are considered the
primary targets of DENV infection in vivo. Several candidate
receptors for DENV have been suggested on different cell types
[6], including dendritic cell-specific intercellular adhesion mole-
cule-3-grabbing non-integrin (DC-SIGN) on dendritic cells [7], the
mannose receptor on macrophages [8] and the Fc-receptor on
macrophages and monocytes after secondary infection with a
heterologous serotype [4,6]. Enhanced infection of immune cells,
due to pre-existing non-neutralizing antibodies, and the resulting
cytokine storm have been suggested to be involved in DHF/DSS
development [3,4].
However, direct infection of endothelial cells may be an
additional factor contributing to DENV-increased vascular per-
meability. The presence of DENV-infected endothelial cells was
demonstrated in murine models, and DENV antigens were found
in endothelial cells in patient autopsy samples [9–14]. In vitro,
DENV has been shown to replicate in primary macrovascular
endothelial cells and in endothelial cell lines of macrovascular and
microvascular origin [14–20]. Microarray analysis of DENV-
infected endothelial cells revealed several differentially expressed
genes involved in stress, cell adhesion, wounding, inflammatory
and antiviral pathways [21–23]. In particular, infection of human
endothelial cells with DENV resulted in transcriptional up-
regulation and secretion of various cytokines, including interleukin
(IL)-6, IL-8 and tumor necrosis factor (TNF)-a [24–28], which are
also highly upregulated in the sera of patients with DHF and may
contribute to increased endothelial cell permeability [27,29].
Increased vascular permeability of HMEC-1 cells infected with
DENV was associated with actin reorganization and alterations in
the expression and distribution of adherens and tight junctional
proteins involved in endothelial cell integrity [20,26]. Also DENV-
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induced changes in surface and soluble vascular endothelial
growth factor (VEGFR)-2 expression were implicated in plasma
leakage in DHF [30]. Moreover, DENV infection was shown to
alter the production of various coagulation factors in endothelial
cells, including increased expression of thrombomodulin [31–33],
downregulation of the cytoprotective protein C pathway [34],
reduced secretion of tissue plasminogen activator (tPA) [25,31]
and upregulated expression of E-selectin, resulting in increased
adherence of platelets to the infected endothelial cells [35]. Thus,
various mechanisms may act in concert in DENV-infected
endothelial cells to contribute to the vascular leakage and
thrombocytopenia observed in DSS.
However, the target receptor for DENV in endothelial cells
remains to be identified and inhibitors of endothelial cell infection
by DENV have not yet been reported. Zhang et al. [36] proposed
b3 integrin as a potential DENV receptor and recently, Dalrymple
and Mackow [17] reported that heparan sulfate proteoglycans
(HSPGs) are important for DENV infection in human umbilical
vein endothelial cells (HUVEC). Since DENV-induced plasma
leakage occurs at the level of the microvasculature [37,38] we
studied DENV infection in primary human dermal microvascular
endothelial cells (HMVEC-d) and the microvascular cell line
HMEC-1 [39]. We found that DENV infection of microvascular
endothelial cells is mediated by HSPGs. Therefore, we investigat-
ed whether heparin analogues display anti-DENV activity in these
cells.
Many polyanionic compounds have been developed over the
years to block virus entry. However, the clinical use of these
heparin analogues has been limited because of anticoagulant side-
effects. Chemically sulfated derivatives of the K5 capsular
polysaccharide of Escherichia coli emerged as a promising new class
of antivirals, with activity against human immunodeficiency virus
(HIV) [40], herpes simplex viruses (HSV) [41], human papillo-
maviruses (HPVs) [42] and human cytomegalovirus (HCMV)
[43]. These compounds are synthesized from a polysaccharide that
has the same structure as the biosynthetic precursor of heparin/
heparan sulfate, N-acetyl heparosan [44], but are devoid of
toxicity and anticoagulant activity [45]. We demonstrate that the
highly sulfated K5-OS(H) and K5-N,OS(H) inhibit DENV
attachment and entry in microvascular endothelial cells by
interacting with domain III of the viral envelope protein,
indicating that these agents may represent a promising new class
of anti-DENV agents.
Materials and Methods
Cell lines and virus
The human microvascular endothelial cell line HMEC-1 [39]
was obtained from the Centers for Disease Control and Prevention
(CDC, Atlanta, GA, USA) and was grown in Dulbecco’s Modified
Eagle Medium (DMEM, Invitrogen, Merelbeke, Belgium) supple-
mented with 10% fetal bovine serum (FBS, Integro, Dieren, The
Netherlands), 0.01 M HEPES (Invitrogen) and 1 mM sodium
pyruvate (Invitrogen) at 37uC under 5% CO2. Only cells with
passage number 20 to 25 were used. Primary human dermal
microvascular endothelial cells (HMVEC-d) were purchased from
Lonza (Verviers, Belgium) and grown in microvascular endothelial
cell growth medium (EGM MV, Lonza) at 37uC under 5% CO2.
C6/36 mosquito cells from Aedes albopictus (ATCC) were main-
tained at 28uC and grown in Minimum Essential Medium (MEM,
Invitrogen) supplemented with 10% FBS, 0.01 M HEPES, 2 mM
L-glutamine (Invitrogen) and non-essential amino acids (Invitro-
gen). Baby hamster kidney (BHK) cells were kindly provided by
Dr. M. Diamond (Washington University, St Louis, USA). These
cells were used for virus titration and were grown in DMEM
supplemented with 10% FBS, 0.01 M HEPES and 1 mM sodium
pyruvate at 37uC under 5% CO2.
DENV serotype 2 laboratory-adapted New Guinea C (NGC)
strain (DENV-2), a kind gift from Dr. V. Deubel (Institut Pasteur,
Paris, France), was propagated in C6/36 cells. Supernatant
containing the virus was collected 5 days post-infection and stored
at –80uC. Virus was titrated by the plaque assay using BHK cells.
Ten-fold dilutions of the virus were inoculated on monolayers of
BHK cells cultured in a 6-well plate (International Medical
Products, Watermaal-Bosvoorde, Belgium) for 4 h at 37uC. The
cells were washed two times with growth medium and incubated
with an overlay containing 1% Avicel [46] and DMEM with 2%
FBS in a 1:1 ratio. After 4 days the cells were washed with PBS,
fixed with 70% ethanol and stained with 0.1% crystal violet.
Plaques were counted to determine the viral titer in plaque
forming units per ml (PFU/ml).
Chemicals and antibodies
Heparin, heparan sulfate, chondroitin sulfate A, dermatan
sulfate, BSA and heparinase II were purchased from Sigma-
Aldrich. Escherichia coli K5 polysaccharide derivatives (K5, K5-NS,
K5-OS(L), K5-OS(H), K5-N,OS(L) and K5-N,OS(H)) were
synthesized as described before [47]. The mannose-specific plant
lectin from Hippeastrum hybrid (HHA) (50 kD) was derived and
purified from these plants as described previously [48]. Cilengitide,
a cyclic RGD peptide, was kindly provided by Dr. H. Kessler
(Technische Universita¨t Mu¨nchen, Mu¨nchen, Germany). The
monoclonal antibody against DENV-2 envelope (E) glycoprotein
(clone 3H5) and functional blocking avb3-integrin antibody (clone
LM609) were purchased from Chemicon International/Millipore
(Billerica, MA, USA) and secondary phycoerythrin-conjugated
goat anti-mouse antibody (clone Poly4053) was from Imtec
Diagnostics (Antwerpen, Belgium). Heparan sulfate antibody
(10E4 epitope) was obtained from Immunosource (Zoersel,
Belgium). Anti-vascular endothelial growth factor receptor-2
(VEGFR-2) and anti-platelet endothelial cell adhesion molecule-
1 (PECAM-1/CD31) were purchased from Abcam (Cambridge,
UK), mouse anti-b3 integrin antibody was from Santa Cruz
Biotechnology (Heidelberg, Germany). DC-SIGN, liver/lymph
node-specific intercellular adhesion molecule-3-grabbing integrin
(L-SIGN) and mouse IgG2B isotype control antibodies were
obtained from R&D Systems (Minneapolis, MN, USA). The
mannose receptor antibody (clone 19.2) and mouse IgG2a isotype
control antibody (clone MOPC-173) were from BD Biosciences
(Erembodegem, Belgium).
Flow cytometric analysis of endothelial cell surface
markers
HMEC-1 and HMVEC-d cells were detached by exposure to
non-enzymatic cell dissociation solution (Sigma-Aldrich, Bornem,
Belgium), washed twice with PBS containing 2% FBS, and
incubated at room temperature for 45 min with primary antibody
or FITC-/PE-conjugated antibodies directed against the surface
markers of interest. Next, cells were washed with 2% FBS/PBS
and incubated at room temperature for 30 min with PE- or FITC-
labeled secondary antibodies. Cells incubated with labeled
secondary antibody only or corresponding FITC-/PE-conjugated
isotypic control antibodies were used as negative control. Finally,
cells were washed twice with 2% FBS/PBS, fixed with 2%
paraformaldehyde (PFA, Sigma-Aldrich) in PBS and analyzed by
flow cytometry.
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DENV infection of endothelial cells and monocyte-
derived dendritic cells (MDDC)
HMEC-1 or HMVEC-d cells (16105 cells/well) were seeded in
a gelatin-coated 48-well plate (International Medical Products).
After an overnight incubation, confluent monolayers were infected
with DENV-2 at a multiplicity of infection (MOI) of 1 (unless
otherwise stated) for 4 h at 37uC (in the presence or absence of
compound). Unbound virus was removed by washing twice with
growth medium after which the cells were incubated at 37uC in
fresh culture medium without compounds. Cells were analyzed for
DENV infection by flow cytometry at different time points and the
supernatant was stored at –80uC for viral RNA extraction and
real-time RT-PCR analysis.
MDDC were isolated and infected with DENV-2 as described
previously by Alen et al. [49].
Flow cytometric analysis of DENV-infected cells
HMEC-1, HMVEC-d or MDDC cells were washed with 2%
FBS/PBS, fixed and permeabilized using the Cytofix/Cytoperm
Kit (BD Biosciences, San Diego, CA, USA) according to the
manufacturer’s instructions. The permeabilized cells were stained
with anti-DENV-2 E protein antibody for 30 min on ice, washed
and incubated for 30 min on ice with the secondary PE-conjugated
goat anti-mouse antibody. The stained cells were analyzed by flow
cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA).
Data were analyzed with CellQuest software (BD Biosciences).
RNA extraction and real-time RT-PCR
Viral RNA was extracted from 150 ml of supernatant with the
NucleospinH RNA Virus Kit (Macherey-Nagel, Du¨ren, Germany)
according to the manufacturer’s instructions. RT-PCR was
performed as described previously [49] using the ABI 7500 Fast
Real-Time PCR System (Applied Biosystems, Branchburg, NJ,
USA). Data were analyzed with ABI PRISM 7500 software
(version 2.0.5, Applied Biosystems).
Virus yield reduction assay
BHK monolayers grown in 6-well plates were incubated with
10-fold serial dilutions of supernatant from HMEC-1 cells infected
with DENV-2 in the presence or absence of compound (300 nM).
After 4 h, the medium was removed and the cells were incubated
with Avicel overlay for 4 days after which the plaques were
counted.
Time-of-drug addition assay
HMEC-1 cells were infected as described above. K5-OS(H) and
K5-N,OS(H) were added 30 min prior to, at the moment of, or at
different times post-infection. Compounds were also incubated for
30 min with the DENV-2 inoculum before infection. Four hours
after infection, unbound virus and compounds were removed and
cells were incubated with fresh growth medium for 24 h. DENV
infection of the cells was analyzed by flow cytometry.
Attachment assay
DENV-2 and different concentrations of K5 derivatives were
added to HMEC-1 monolayers at 4uC for 2 h. Next, cells were
washed twice (at 4uC) to remove unbound virus and compound,
incubated for 24 h in growth medium without compound at 37uC
and analyzed by flow cytometry.
For immunofluorescence staining, HMEC-1 cells (56104 cells/
well) were seeded in 8-well Lab-Tek chamber slides (Nalge Nunc
International, Roskilde, Denmark). After 24 h, cells were infected
with DENV-2 at a MOI of 10 in the presence or absence of
compounds for 1 h at 4uC. Unbound virus was removed by
washing 3 times with ice-cold PBS and cells were fixed with 2%
PFA for 15 min at room temperature. Fixed cells were blocked
with 0.5% BSA in PBS for 1 h at room temperature, washed twice
with PBS and incubated with anti-DENV-2 E protein antibody for
2 h. Goat anti-mouse IgG Alexa Fluor 488 (Invitrogen) was used as
secondary antibody, nuclei were stained with DAPI (Invitrogen).
Fluorescence analysis was performed on an Axiovert 200 M
microscope (Carl Zeiss, Go¨tingen, Germany) using an EC Plan-
Neofluar 40X/1.3 oil objective.
Entry assay
DENV-2 was added to HMEC-1 monolayers at 4uC for 2 h to
allow virus attachment. Next, cells were washed twice to remove
unbound virus and incubated with growth medium containing
different concentrations of K5 derivatives at 37uC for 2 h to allow
virus entry. Cells were washed twice and treated with citrate buffer
(citric acid 40 mM, potassium chloride 10 mM, sodium chloride
135 mM, pH 3) for 1 min to inactivate adsorbed but not
internalized virus. Next, cells were incubated for 24 h in growth
medium without compound at 37uC and analyzed by flow
cytometry.
Cytotoxicity assay
Potential cytotoxic effects of the compounds were evaluated by
the MTS method [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Promega, Lei-
den, The Netherlands)]. HMEC-1 cells were seeded at 56103
cells/well in a 96-well plate. After an overnight incubation, growth
medium was removed and cells were incubated with serial
dilutions of the compounds for 48 h. Next, medium was replaced
by 100 ml of 0.02% MTS in PBS and incubated for 2 h at 37uC.
The optical density (OD) was determined at 490 nm and the 50%
cytotoxic concentration (CC50; i.e. drug concentration needed to
reduce the total cell number by 50%) was calculated.
Heparinase II treatment
Confluent monolayers of HMEC-1 cells were incubated with
heparinase II (0.5 to 10 Sigma Units/ml diluted in PBS) for 2 h at
37uC to selectively remove glycosaminoglycan (GAG) chains. The
cells were subsequently infected as described above. To confirm
cleavage by heparinase II, cells were collected and stained with a
mouse monoclonal anti-heparan sulfate antibody, washed with 2%
FBS/PBS, incubated with a secondary PE-labeled goat anti-mouse
antibody and analyzed by flow cytometry.
Surface plasmon resonance (SPR) analysis
Recombinant envelope protein (domain III) of DENV-2 (amino
acid sequence: SYSMCTGKFKIVKEIAETQHGTIVIRVQYE
GDGSPCKIPFEIMDLEKRHVLGRLITVNPIVTEKDSPVNIE-
AEPPFGDSYIIIGVEPGQLKLDWFKKGSSIGQMFETTMR-
GAKRMA) (GenWay Biotech Inc., San Diego, CA, USA) was
covalently immobilized on a CM5 sensor chip in 10 mM
sodium acetate, pH 5.5, using standard amine coupling
chemistry. The chip density was 1800 resonance units (RU).
A reference flow cell was used as a control for non-specific
binding and refractive index changes. All interaction studies
were performed at 25uC on a Biacore T200 instrument (GE
Healthcare, Uppsala, Sweden). The compounds K5, K5-OS(H)
and K5-N,OS(H) were serially diluted in HBS-P (10 mM
HEPES, 150 mM NaCl and 0.05% surfactant P20; pH 7.4)
and 10 mM CaCl2 covering a concentration range
between 12 nM and 1.5 mM, by using five-fold dilution steps.
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Anti-DENV-2 E antibody and mouse IgG2B isotype control
antibody were included as positive and negative control,
respectively. Samples (in duplicate) were injected for 2 min at
a flow rate of 45 ml/min and the dissociation was followed for 3
min. Several buffer blanks were used for double referencing.
The CM5 sensor chip surface was regenerated with a single
injection of 50 mM NaOH. For kinetic analysis the same
experimental setup was applied but with a chip density of 680
RU. The experimental data were fit using the 1:1 binding
model (Biacore T200 Evaluation software 1.0) to determine the
binding kinetics.
To evaluate competition between recombinant E protein
domain III and K5 derivatives for binding to heparin, 30 RU of
biotinylated heparin (Sigma) were captured on a streptavidin (SA)
sensor chip. The analytes, 400 nM of E protein domain III alone
or premixed with K5 derivatives or heparin (at different
concentrations), were diluted in HBS-EP (10 mM HEPES,
150 mM NaCl, 3 mM EDTA and 0.05% surfactant P20;
pH 7.4). Samples were injected for 2 min at a flow rate of
30 ml/min, followed by a dissociation phase of 2 min. The SA
sensor chip surface was regenerated with a single injection of 50
mM NaOH and washed with buffer for 6 min.
Figure 1. Time- and dose-dependent DENV infection of primary microvascular endothelial HMVEC-d cells and the endothelial cell
line HMEC-1. HMEC-1 (A, C) and HMVEC-d cells (E) were infected with DENV-2 at a MOI 1. Viral infectivity was quantified at different times after
infection by flow cytometry using an anti-DENV-2 specific antibody (A, E). The amount of viral RNA was determined in the supernatant of infected
HMEC-1 cells by means of real-time RT-PCR at different times after infection (C). Alternatively, HMEC-1 (B, D) and HMVEC-d cells (F) were treated with
medium only (mock) or infected with DENV at a MOI of 1, 2 or 4. Viral infectivity was quantified 24 h post infection by flow cytometry (B, F). The
amount of viral RNA was determined in the supernatant of infected HMEC-1 cells at 24 h post infection by means of real-time RT-PCR (D). The means
and standard deviations of three independent experiments are shown.
doi:10.1371/journal.pone.0074035.g001
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Results and Discussion
Microvascular endothelial cells are permissive for DENV-
2 infection and replication. The microvascular endothelium
forms the primary fluid barrier of the capillaries, but the extent to
which the endothelial cells contribute to increased capillary
permeability in DHF/DSS is not well understood [37,38].
However, it is likely that infected endothelial cells contribute to
increased viral spread and that viral antigens expressed by these
cells target the endothelium for immune attack. As such, it is
important to gain further insight into the mechanism by which
DENV infects endothelial cells and to search for ways to interfere
with this process.
We investigated DENV infection and replication in microvas-
cular endothelial cells by means of flow cytometry and RT-PCR at
different time points post-infection. When HMEC-1 cells were
infected with DENV-2 at a MOI of 1, 11% of the cells were
infected at 24 h post-infection (Fig. 1A). This number could be
increased up to 49% when a MOI of 4 was used (Fig. 1B).
Histograms representing flow cytometric analyses are shown in
Fig. S1. The infected cells were susceptible to DENV replication as
shown by the increase in viral load 24-48 h post-infection (Fig. 1C,
D).
These levels of infection are in agreement with a previous study
by Zamudio-Meza et al. [16], who reported a productive infection
in 25% of HMEC-1 cells infected with DENV-2 at an MOI of 3
(compared with 21% infection obtained at an MOI of 2 in our
study). Dalrymple and Mackow [17] obtained an infection rate of
more than 80% in primary endothelial cells (human umbilical vein
endothelial cells; HUVECs). However, these studies were
performed with DENV serotype 4, whereas we used DENV
serotype 2. Additionally, HUVECs are macrovascular endothelial
cells and it is well-established that the functional differences that
exist between large and small vessels are reflected by morpholog-
ical and phenotypic differences between macrovascular and
microvascular endothelium [50], including the expression of
specific surface markers, which may ultimately determine DENV
attachment and entry.
To our knowledge, DENV infection in primary microvascular
endothelial cells has never been studied. Therefore, we decided to
investigate whether human primary microvascular endothelial
cells of dermal origin (HMVEC-d) are susceptible to DENV-2
infection. Under the same experimental conditions as used for
HMEC-1 cells, 7% to 23% of HMVEC-d cells were infected with
DENV at a MOI of 1 or 4, respectively (Fig. 1 E, F). This suggests
that multiple parameters, including origin of the cells, passage
number, macrovascular versus microvascular endothelium, may
affect DENV infectivity in endothelial cells. Indeed, significant
differences in DENV infection rate and cell surface expression of
adhesion molecules were demonstrated using microvascular
endothelial cell lines of liver and dermal origin [19]. Also the
DENV NS1 protein, which is secreted from infected cells, was
shown to preferentially bind to cultured human microvascular
compared to aortic or umbilical vein endothelial cells [51].
However, the decrease in the number of infected HMEC-1 and
HMVEC-d cells that was observed after 24 h and the stabilization
of virus titer after 48–72 h (Fig. 1) correlate with the findings
obtained in HUVECs [23] and were suggested to be the result of
an IFN-b response induced in DENV-infected endothelial cells,
which protects the neighboring cells from DENV infection.
Therefore, in the following experiments we preferred to investigate
viral infectivity and replication after 24 h and 48 h, respectively.
Expression of putative DENV-2 receptors on
microvascular endothelial cells
DENV has been shown to infect various cell types by binding to
different receptors, i.e. DC-SIGN (CD209) on dendritic cells, the
mannose receptor (CD206) on macrophages and the Fc-receptor
on monocytes and macrophages [6–8], but the receptor for DENV
on endothelial cells has not yet been revealed. DC-SIGN and the
mannose receptor were not detected on the surface of HMEC-1
and HMVEC-d cells (Fig. 2). Also, these cells did not express L-
SIGN, which is found on endothelial cells of liver and lymph nodes
[52]. Other typical endothelial cell markers, such as PECAM-1
(CD31) and vascular endothelial growth factor receptor (VEGFR)-
2 could be detected on the endothelial cells. However, it should be
noted that primary HMVEC-d cells expressed higher levels of
CD31, compared with the HMEC-1 cell line, whereas both cell
types expressed equally (low) levels of VEGFR-2 (Fig. 2).
Zhang et al. [36] proposed b3 integrin as a potential receptor for
DENV on endothelial cells. Although we confirmed that this
integrin is present on HMEC-1 cells (Fig. S2), pre-treatment of the
cells with a functional blocking antibody directed at b3 integrin or
with Cilengitide, a RGD-containing peptide [53], did not abrogate
DENV infection (Fig. S2), suggesting that b3 integrin does not
mediate DENV infection in microvascular endothelial cells.
Recently, Dalrymple and Mackow [17] showed that HSPGs
mediate DENV serotype 4 infection in HUVECs. We found that
HSPGs are highly expressed on the surface of HMEC-1 and
Figure 2. Expression of surface molecules on HMEC-1 and
HMVEC-d cells as determined by flow cytometry. HMEC-1 and
HMVEC-d cells were stained with antibodies against different DENV
receptors or endothelial cell markers. The mean fluorescence intensities
for DC-SIGN, L-SIGN, mannose receptor (MR), heparan sulfate (HS),
vascular endothelial growth factor receptor (VEGFR)-2 and CD31
(PECAM-1) are shown (after background reduction in the presence of
labeled secondary antibody only or corresponding FITC-/PE-conjugated
isotypic control antibody).
doi:10.1371/journal.pone.0074035.g002
Table 1. Antiviral activity of heparin and heparan sulfate
analogs against DENV-2 in HMEC-1 cells.
Compound EC50 (mg/mL) EC50 (mM)
Heparin 1.060.3 0.07760.023
Heparan sulfate 60610 6.061.0
Chondroitin sulfate A 6765 4.260.3
Dermatan sulfate 46617 3.360.9
EC50: effective concentration or drug concentration required to inhibit DENV-2
infection in HMEC-1 cells by 50% as measured by flow cytometry. The means 6
standard deviations for three independent experiments are shown.
doi:10.1371/journal.pone.0074035.t001
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HMVEC-d cells (Fig. 2). Also, HSPGs have been reported to
mediate DENV infection in various other cell types (e.g. Vero
monkey kidney cells, BHK cells, and several human liver cell lines)
[54–59]. Hence, the potential role of HSPGs in DENV-2 infection
of microvascular endothelial cells was further investigated.
DENV infection of HMEC-1 cells is mediated by heparin-
containing glycosaminoglycans (GAGs)
HSPG receptors are composed of a core protein and different
GAG side-chains [60]. Therefore, the anti-DENV activity of
naturally occurring GAGs (heparin, heparan sulfate, chondroitin
Figure 3. Anti-DENV-2 activity of sulfated GAGs. HMEC-1 cells were infected with DENV-2 at a MOI 1. Viral infectivity was quantified 24 h after
infection by flow cytometry using an anti-DENV-2 specific antibody. Heparin (A), heparan sulfate (B), chondroitin sulfate A (C) and dermatan sulfate
(D) dose-dependently inhibited DENV-2 infection in HMEC-1 cells. Data represent the % of infected cells relative to the positive control (DENV-2
infected cells). The means and standard deviations of three independent experiments are shown.
doi:10.1371/journal.pone.0074035.g003
Figure 4. Heparinase II treatment of HMEC-1 cells reduces DENV-2 infectivity. HMEC-1 cells were treated with 10 U/mL of heparinase II (A).
Cell surface expression of heparan sulfate was analyzed by flow cytometry and plotted against the number of events (counts). The dashed line
represents untreated HMEC-1 cells, the full histogram indicates heparinase II-treated HMEC-1 cells. Background in the absence of primary antibody is
shown by the full line. HMEC-1 cells were treated with different concentrations of heparinase II (0 to 10 U/mL) and subsequently infected with DENV-2
at a MOI 1 (B). Viral infectivity was quantified by flow cytometry using an anti-DENV-2 specific antibody. The means and standard deviations of three
independent experiments are shown.
doi:10.1371/journal.pone.0074035.g004
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sulfate A and dermatan sulfate) was investigated. A dose-
dependent inhibitory activity was observed for all four GAGs by
flow cytometry for viral antigen expression (Fig. 3). EC50 values
were determined for each compound and are shown in Table 1.
Heparin showed the most pronounced antiviral activity with an
EC50 value (i.e. compound concentration that inhibits DENV
infection by 50%) of 77 nM and could inhibit DENV-2 infection of
HMEC-1 cells up to 93% at the highest concentration tested
(7.7 mM). Heparan sulfate, chondroitin sulfate A and dermatan
sulfate, in contrast, only showed antiviral activity (35–80%) at
micromolar concentrations (3–6 mM).
To further analyze the role of HSPGs in DENV-2 infection of
microvascular endothelial cells, HMEC-1 cells were treated with
different concentrations of heparinase II, which cleaves sulfated
polysaccharide chains containing 1–4 linkages between uronic acid
and hexosamine residues. Thus, the enzyme is able to cleave
heparan sulfate and to a lesser extent heparin (relative activity ,
2:1) [61]. Incubation with 10 U/ml heparinase II led to a decline
of 70% in heparan sulfate surface expression (Fig. 4A) and a 58%
reduction in the number of infected cells (Fig. 4B). As treatment
with heparinase II had no effect on cell viability, the reduced
number of infected cells was not caused by toxic effects on
HMEC-1 cells. Pretreatment of endothelial cells with chondroi-
tinase ABC (which cleaves dermatan sulfate and chondroitin
sulfate) had no effect on DENV-2 infection of HMEC-1 cells (data
not shown). These data suggest that DENV-2 infection of HMEC-
1 cells specifically requires the interaction of DENV with heparin.
Inhibition of DENV infection by Escherichia coli K5
polysaccharide derivatives
Many polyanions and heparin analogs have been investigated
for their use as antiviral drugs over the past decades but their
clinical use has been limited because of anticoagulant activity and
poor oral bioavailability [62]. Sulfated derivatives of the K5
polysaccharide of Escherichia coli contain a backbone with the same
structure as the biosynthetic precursor of heparin and HS, but are
devoid of anticoagulant activity [45]. Therefore, several K5
derivatives (i.e. the native form K5, N-sulfated K5 (K5-NS), O-
sulfated K5-OS(L) and N,O-sulfated K5-N,OS(L) with low degree
of sulfation and K5 with high degree of sulfation K5-OS(H) and
K5-N,OS(H), see Table 2), were evaluated for their antiviral
activity against DENV-2 in microvascular endothelial cells.
K5 and K5-NS did not inhibit DENV-2 infection even at the
highest concentration tested (3 mM), while K5-OS(L) and K5-
N,OS(L) only inhibited DENV-2 infection by 42 and 19%,
respectively, when administered at 3 mM, but lost activity at 5-fold
lower concentrations. Instead the highly sulfated K5-OS(H) and
K5-N,OS(H) proved to be very active compounds, which dose-
dependently inhibited DENV-2 infection in the nanomolar range,
with an EC50 value of 113680 and 111650 nM, respectively (Fig.
5, Table 3). The antiviral activity of the K5 derivatives was not due
to cytotoxic effects (CC50 . 10 mM), resulting in a favorable
selectivity index (SI) of 176 and 113 for K5-OS(H) and K5-
N,OS(H), respectively (Table 3). Both compounds suppressed
DENV-2 replication (measured by RT-PCR) with an EC50 of
168688 and 201657 nM, respectively (data not shown). To study
the effect of sulfated K5 derivatives on infectious virus production,
a virus yield reduction assay was performed in BHK cells using
supernatant from HMEC-1 cells, infected with DENV in the
presence (300 nM) or absence of the compounds. As expected,
heparin (97%), K5-OS(H) (94%) and K5-N,OS(H) (91%), but not
K5 (7%) significantly reduced the formation of plaques induced by
infectious virus released from HMEC-1 cells (Fig. 6).
Next, we investigated whether the compounds also display
antiviral activity in primary HMVEC-d cells. Again, K5-OS(H)
and K5-N,OS(H) dose-dependently inhibited DENV-2 infection
(EC50 value of 266 and 330 nM, respectively) (Fig. 5), whereas the
other K5 derivatives were ineffective (data not shown).
Together, these data indicate that the highly sulfated K5
derivatives inhibit the interaction of DENV with HSPGs on
endothelial cells. As such, the 3-fold lower activity of the
compounds in HMVEC-d cells, compared with HMEC-1 cells,
may be explained by the lower expression of HSPGs in the
primary ECs, as shown by flow cytometric analysis (Fig. 2). Our
findings also suggest that the antiviral activity of the K5 derivatives
Table 2. Chemical features of sulfated K5 derivatives.
Compound MW(kDa) SO3
2/COO2 ratio Chemical composition (%)
Glc-NSO3
2 Glc-6SO3
2 GlcA-OSO3
2 GlcA2,3SO3
2a Nonsulfated GlcA
K5 30 0 0 0 0 0 100
K5-NS 15 1.00 100 0 0 0 100
K5-OS(L) 14 1.41 0 90 ,10 0 .90
K5-OS(H) 11 3.77 0 100 0 100 0
K5-N,OS(L) 13 1.70 100 90 ,10 0 .90
K5-N,OS(H) 15 3.84 100 100 30 70 0
aGlcA2SO3
2 or GlcA3SO3
2.
doi:10.1371/journal.pone.0074035.t002
Table 3. Antiviral activity and cytotoxicity of K5 derivatives in
HMEC-1 cells.
Compound MW (kDa) CC50 (mM) EC50 (mM) SI
K5 30 1062 . 3
K5-NS 15 . 50 . 3
K5-OS(L) 14 . 50 . 3
K5-OS(H) 11 2062 0.1160.08 176
K5-N,OS(L) 13 1762 . 3
K5-N,OS(H) 15 1361 0.1160.05 113
CC50: cytotoxic concentration or drug concentration required to reduce cell
viability by 50% as measured by MTS assay.
EC50: effective concentration or drug concentration required to inhibit DENV-2
infection in HMEC-1 cells by 50% as measured by flow cytometry. The means 6
standard deviations for three independent experiments are shown.
SI: selectivity index, ratio of CC50/EC50.
doi:10.1371/journal.pone.0074035.t003
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depends on their degree of sulfation, but not on the position of the
sulfate groups (O versus N). The requirement for highly sulfated
compounds may in part explain why heparin was almost 100-fold
more effective than heparan sulfate in inhibiting DENV infection
of endothelial cells. Alternatively, the composition of the
disaccharide unit may explain the marked difference in antiviral
activity of these GAGs; whereas heparan sulfate is composed of
glucuronic acid (linked to N-acetylglucosamine), heparin contains
mainly iduronic acid. The latter hypothesis suggests that the anti-
DENV activity of K5 derivatives may be improved by replacing
glucuronic acid with iduronic acid [63].
Since dendritic cells are considered the primary target cells of
DENV in vivo, we next investigated whether the compounds
display antiviral activity in monocyte-derived dendritic cells
(MDCC). As a positive control, we used the carbohydrate-binding
agent HHA, which has been shown to interrupt the interaction of
DENV with DC-SIGN, the cognitive receptor for DENV on
MDDC [49]. HHA displayed a potent inhibition of DENV
infection in MDCC (EC50 value of 5.662.8 nM). Interestingly,
also K5-OS(H) and K5-N,OS(H) impaired DENV-2 infection of
MDCC (Fig. 5), although to a lesser extent than HHA. However,
whereas K5-OS(H) almost completely retained antiviral activity in
Figure 5. Dose-dependent antiviral activity of K5-OS(H) and K5-N,OS(H) in DENV-infected endothelial cells and MDDC. HMEC-1 or
HMVEC-d cells (A, B) and MDDC (C, D) were infected with DENV-2 at a MOI 1 in the presence of different concentrations of K5-OS(H) (A, C) or K5-
N,OS(H) (B, D). Viral infectivity was quantified 24 h (endothelial cells) or 48 h (MDCC) post infection by flow cytometry using an anti-DENV-2 specific
antibody. Data represent the % of infected cells relative to the virus control. The means and standard deviations of three independent experiments
are shown.
doi:10.1371/journal.pone.0074035.g005
Figure 6. Virus yield reduction assay on BHK cells. HMEC-1 cells were infected with DENV-2 (MOI 1) in the presence or absence of the
compounds (300 nM). After 24 h, supernatant was collected and transmitted to a monolayer of BHK cells at serial 10-fold dilutions. Plaques were
counted after 4 days. Left: A representative virus yield reduction assay of dilution 1021 is shown: Cell control (A), virus control (B), heparin (C), K5-
OS(H) (D), K5-N,OS(H) (E) and K5 (F). Right: The % cytopathic effect (CPE) relative to the virus control 6 standard deviation is shown.
doi:10.1371/journal.pone.0074035.g006
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Figure 7. K5 derivatives inhibit the early steps of DENV infection in microvascular endothelial cells. K5-OS(H) (A) and K5-N,OS(H) (B) (500
nM) were added prior to (–30 min), together with (0 min), or at different times post-infection. The compounds were also incubated with virus
inoculum for 30 min at 37uC before infection (virion). Viral infectivity was quantified after 24 h by flow cytometry using an anti-DENV-2 specific
antibody. The percentage of infected cells relative to the virus control and standard deviation of 3 independent experiments are shown. Effect of K5-
OS(H) and K5-N,OS(H) on DENV-2 attachment (C). HMEC-1 cells were incubated during 2 h at 4uC with DENV-2 in the presence or absence of various
concentrations of compound. Next, cells were washed and after 24 h infection was analyzed by flow cytometry. Effect of K5-OS(H) and K5-N,OS(H) on
DENV-2 entry (D). DENV-2 was allowed to attach to HMEC-1 cells for 2 h at 4uC. Unbound virus was washed away, various concentrations of
compounds were added and temperature was raised to 37uC for 2 h to allow virus entry. Cells were washed and after 24 h infection was analyzed by
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MDDC (EC50 value of 291685 nM versus 113680 nM in
endothelial cells), K5-N,OS(H) was less effective (EC50 value of
2.661.1 mM).
We found high expression of DC-SIGN, but also of heparan
sulfate on the surface of MDCC (Fig. S3). Various viruses for
which specific cellular receptors have been identified are known to
use HSPGs as primary attachment receptors [64]. In particular,
both HSPGs and DC-SIGN were shown to be required for
attachment of HIV-1 and HSV-1 to dendritic cells [65,66]. As
such, HSPGs may serve as initial attachment factors to concen-
trate DENV on the cell surface and sulfated K5 derivatives may
impair this initial cell attachment step. Alternatively (or addition-
ally), the antiviral activity in dendritic cells may be caused by the
capacity of these rather bulky compounds to sterically impair the
interaction of DENV with DC-SIGN.
In either case, one would expect a comparable antiviral activity
of both highly sulfated compounds in dendritic cells, as demon-
strated in endothelial cells. However, whereas we found K5-OS(H)
to be almost 10-fold more active than K5-N,OS(H) against DENV
infection in dendritic cells, K5-N,OS(H) was shown to be ,20-
and 80-fold more efficient than K5-OS(H) against HIV-1 and
HSV-1, respectively [45]. Thus, although K5-OS(H) and K5-
N,OS(H) are structurally very similar and contain a comparable
degree of sulfation, the specific arrangement of sulfate groups
flow cytometry. The percentage of infected cells relative to the virus control and standard deviation of 3 independent experiments are shown.
Immunofluorescent staining of DENV-2 attachment to HMEC-1 cells (E). HMEC-1 cells were incubated with DENV-2 in the presence or absence of K5
derivatives (1.5 mM) on ice. Next, the nuclei (blue) and DENV-2 particles (green) were stained. K5-OS(H) and K5-N,OS markedly reduced DENV-2
attachment to HMEC-1 cells. CC: cell control, VC: virus control.
doi:10.1371/journal.pone.0074035.g007
Figure 8. Surface plasmon resonance (SPR) analysis of the interaction between K5 derivatives and the DENV envelope protein.
Sensorgrams show the binding of anti-DENV E antibody (positive control) and isotype antibody (negative control) (A), K5 (B), K5-OS(H) (C) and K5-
N,OS(H) (D) to immobilized DENV E domain III. The binding curves of 0 to 120 s show the association, whereas those of 120 to 300 s show the
dissociation phase. The y axis indicates the resonance signal as shown in resonance units (RU). Binding of DENV E domain III to immobilized heparin
in the presence of different concentrations of compound (E). Heparin, K5-OS(H) and K5-N,OS(H) dose-dependently inhibited the interaction of
domain III with immobilized heparin, whereas K5 was ineffective. Shown are the RU (% of domain III binding to the heparin chip).
doi:10.1371/journal.pone.0074035.g008
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along the sugar chain is sufficient to elicit a different biological
activity.
K5-OS(H) and K5-N,OS(H) interfere with the early steps of
DENV-2 infection
In order to determine at which stage of infection the highly
sulfated K5 derivatives exert their antiviral activity, time-of-drug-
addition experiments were performed. As shown in Fig. 7, pre-
incubation of the virus inoculum with 0.5 mM of K5-OS(H) or K5-
N,OS(H) for 30 min before infection almost completely suppressed
DENV-2 infection of HMEC-1 cells. Similarly, when the
compounds were added 30 min prior to, or at the time of
infection, complete protection was observed. The inhibitory
activity of the compounds steadily diminished when added at
later time points after infection, i.e. from .85% and 65%
inhibition when added at 30 min or 1 h after infection,
respectively, to complete loss of activity when added 2-3 h post
infection. Both highly sulfated K5 derivatives failed to display any
inhibitory activity when allowed to interact with the HMEC-1 cell
surface for 2 h, and subsequently washed away before infection of
the cells (data not shown). These data indicate that K5-OS(H) and
K5-N,OS(H) do not bind to cellular surface molecules but rather
interact with the DENV envelope protein by which the early steps
of virus infection (attachment and/or entry) are inhibited.
Therefore, we investigated in more detail the effects of K5
derivatives on DENV attachment and entry. In a first set of
experiments, HMEC-1 cells were incubated with DENV-2 and
various concentrations of K5-OS(H) and K5-N,OS(H) for 2 h at
4uC, a condition that allows only virus attachment. Next, unbound
virus and compound were washed away and cells were incubated
for 24 h at 37uC. Both K5-OS(H) and K5-N,OS(H) prevented
DENV-2 attachment to HMEC-1 cells (EC50 value of 1636101
nM and 129677 nM for K5-OS(H) and K5-N,OS(H) respective-
ly, Fig. 7C), while K5 proved to be inactive (data not shown).
Consistent with these results, immunofluorescence staining of
HMEC-1 cells, incubated with DENV-2 in the presence or
absence of the compounds for 1 h at 4uC showed that K5-OS(H)
and K5-N,OS(H) markedly reduce DENV-2 attachment to
HMEC-1 cells (Fig. 7E).
To determine the effect of K5 derivatives on viral entry, DENV-
2 was allowed to attach to HMEC-1 cells at 4uC for 2 h. Next,
unbound virus was washed away, different concentrations of
compounds were added and the temperature was shifted to 37uC
for 2 h to allow viral entry. Under these conditions, K5-OS(H) and
K5-N,OS(H) retained their antiviral activity and even displayed a
slightly higher activity than in the standard antiviral assay (EC50
values of 84640 nM and 40614 nM against virus entry versus
113680 and 111650 nM in the standard assay for K5-OS(H) and
K5-N,OS(H), respectively, Fig. 7D), whereas K5 remained
inactive (data not shown).
These data indicate that highly sulfated K5 derivatives inhibit
DENV-2 infection of HMEC-1 cells by interfering with both viral
attachment and entry. Similarly, K5-OS(H) and K5-N,OS(H)
were shown to exert a post-attachment inhibitory activity against
HIV, HSV-1 and HPV [40–42], whereas 100-fold higher drug
concentrations were required to inhibit HCMV entry as compared
to virus adsorption [43].
E. coli K5 derivatives inhibit DENV infection by interacting
with the viral envelope (E) protein
To evaluate whether the highly sulfated K5-OS(H) and K5-
N,OS(H) prevent DENV attachment and entry by interacting with
the viral envelope protein, surface plasmon resonance (SPR) was
used. Domain III of the DENV E protein has been implicated in
receptor binding and contains two putative GAG binding sites,
which are assumed to be involved in cell surface GAG interaction
[54,67]. Therefore, in a first set of experiments, recombinant
DENV-2 E protein (domain III) was covalently immobilized on a
CM5 sensor chip. Five-fold serial dilutions of K5, K5-OS(H) and
K5-N,OS(H) (range 12 to 1500 nM) were exposed to the
immobilized protein. Figure 8 demonstrates that both K5-OS(H)
and K5-N,OS(H) bind to E protein domain III in a concentration-
dependent manner. K5 in contrast, which showed no antiviral
activity, was unable to bind the E protein. For kinetic analysis two-
fold serial dilutions of K5-OS(H) and K5-N,OS(H) were used. A
1:1 Langmuir kinetic fit was applied to obtain the association rate
constant ka, dissociation rate constant kd, and the dissociation
constant KD. The interaction of K5-OS(H) and K5-N,OS(H) with
DENV E protein was characterized by ka-values of 3.0610
4 and
2.86104 M21s21 and kd-values of 1.8610
23 and 1.461023 s21
which result in comparable high-affinity binding (KD of 59 nM
and 50 nM for K5-OS(H) and K5-N,OS(H), respectively).
Next, to mimic the interaction of DENV with cell-associated
HSPGs, biotinylated heparin was captured on a streptavidin
sensor chip and the binding of DENV E domain III to heparin was
evaluated in the presence or absence of K5 derivatives. As shown
in Fig. 8E, the binding of DENV E domain III to captured heparin
was dose-dependently inhibited when domain III was injected
together with heparin, K5-OS(H) or K5-N,OS(H). A complete
inhibition of domain III binding was obtained in the presence of
60 nM of heparin or 12 nM of K5-OS(H) or K5-N,OS(H). In
contrast, K5 was unable to abrogate the interaction of domain III
with the heparin chip when administered at concentrations up to
300 nM (Fig. 8). Thus, both assays indicate that, by occupying the
GAG binding sites on the viral E protein, K5-OS(H) and K5-
N,OS(H) may prevent the initial attachment step (and subsequent
entry) of the virus to endothelial cells.
In conclusion, our results indicate that DENV-2 infection of
microvascular endothelial cells critically depends upon the
interaction of HSPGs with the viral envelope protein. This
interaction can be inhibited by natural GAGs or by highly sulfated
Escherichia coli K5 derivatives. These compounds are devoid of
anticoagulant activity, not cytotoxic and able to inhibit DENV
attachment and entry. Thus, K5 derivatives represent a new class
of anti-DENV antivirals that, via their inhibitory activity in
endothelial and dendritic cells, may inhibit the cytokine storm that
is thought to induce vascular leakage in DHF/DSS. Pharmaco-
kinetic and bioavailability studies should be carried out to
determine the potential of these compounds as anti-DENV agents.
Supporting Information
Figure S1 Infection of endothelial cells by DENV.
HMEC-1 and HMVEC-d cells were treated with medium alone
(A, E) or infected with DENV-2 at a MOI of 1, 2 or 4 (C, G). Viral
infectivity was quantified 24 h after infection by flow cytometry
using an anti-DENV specific antibody (full histogram). Alterna-
tively, HMEC-1 (D) and HMVEC-d (H) cells were infected with
DENV-2 at a MOI of 1 and viral infectivity was quantified by flow
cytometry after 24, 48 or 72 h post-infection. Background signal
was determined by staining the cells with secondary PE-
conjugated antibody only (B, F).
(TIF)
Figure S2 The expression of b3 integrin on HMEC-1
cells was measured by flow cytometry (A). Shown is the
surface expression of the specific marker (full histogram) and
background in the absence of primary antibody (dashed line).
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HMEC-1 cells were pre-treated with a functional blocking
antibody against b3 integrin (B) or Cilengitide (C) and infected
with DENV-2 at a MOI 1. Viral infectivity was quantified 24 h
after infection by flow cytometry using an anti-DENV-2 specific
antibody.
(TIF)
Figure S3 Expression of heparan sulfate (A) and DC-
SIGN (B) on MDDC. Shown is the surface expression of the
specific marker (full histogram) and background in the absence of
primary antibody (dashed line).
(TIF)
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